Skip to main navigation Skip to search Skip to main content

Extracellular nicotinamide phosphoribosyltransferase, a new cancer metabokine

  • Ambra A. Grolla
  • , Cristina Travelli
  • , Armando A. Genazzani
  • , Jaswinder K. Sethi

Research output: Contribution to journalReview articlepeer-review

Abstract

In this review, we focus on the secreted form of nicotinamide phosphoribosyltransferase (NAMPT); extracellular NAMPT (eNAMPT), also known as pre-B cell colony-enhancing factor or visfatin. Although intracellular NAMPT is a key enzyme in controlling NAD metabolism, eNAMPT has been reported to function as a cytokine, with many roles in physiology and pathology. Circulating eNAMPT has been associated with several metabolic and inflammatory disorders, including cancer. Because cytokines produced in the tumour micro-environment play an important role in cancer pathogenesis, in part by reprogramming cellular metabolism, future improvements in cancer immunotherapy will require a better understanding of the crosstalk between cytokine action and tumour biology. In this review, the knowledge of eNAMPT in cancer will be discussed, focusing on its immunometabolic function as a metabokine, its secretion, its mechanism of action and possible roles in the cancer micro-environment.

Original languageEnglish
Pages (from-to)2182-2194
Number of pages13
JournalBritish Journal of Pharmacology
DOIs
Publication statusPublished - 2016

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Extracellular nicotinamide phosphoribosyltransferase, a new cancer metabokine'. Together they form a unique fingerprint.

Cite this